H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results from the Phase 2 TRANQUILITY trial of Pacibekitug.

H.C. Wainwright Reiterated a Buy Rating on Tourmaline Bio (TRML), After Promising Results by Pacibekitug

A scientist in a white lab coat working at a bench with biopharmaceutical equipment.

Analyst Chen noted the results from the Phase 2 TRANQUILITY trial showed a significant reduction in high-sensitivity C-reactive protein (hs-CRP) levels in patients with kidney disease. The candidate also achieved a rapid and durable reduction in hs-CRP compared to the existing Ziltivekimab. Chen believes this can increase the potential market share of Tourmaline Bio, Inc.’s (NASDAQ:TRML) Pacibekitug.

Tourmaline Bio, Inc. (NASDAQ:TRML) is a late-stage clinical biotechnology company developing treatments for life-altering immune and inflammatory diseases. Pacibekitug (TOUR006), is the company’s lead product. It is a fully human monoclonal antibody designed to have a long half-life, high binding affinity to IL-6, and low immunogenicity.

While we acknowledge the potential of TRML as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRML and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.